Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 7, 2000, Pages 665-672

  Robert, J ^a   Trystram, D ^a   Truffot Pernot, C ^a,b   Carbonnelle, B ^b   Grosset, J ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Epidemiology; M. tuberculosis; Resistance

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0033942082     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Quenum B, Hubert B, Grosset J. La tuberculose en France de 1970 à 1989. Bull Epidémiol Hebdo 1989: 10-11.
2. Canetti G, Gay P, Le Lirzin M. Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1962 to 1970: a national survey. Tubercle 1972; 53: 57-83.
3. Huret B, Haury B, Moyse C. Les cas de tuberculose déclarés en France en 1992. Bull Epidémiol Hebdo 1993; 52: 243-245.
4. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev Tuberc Pneumol 1963; 27: 217-272.
5. Inderlied C B, Salfinger M. Antimycobacterial agents and susceptibility tests. In: Murray P R, Baron E J, Pfaller M A, et al., eds. Manual of clinical microbiology, 7th ed. Washington DC: ASM Press, 1999: 1601-1623.
6. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
7. Pablos-Méndez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis drug resistance 1994-1997. N Engl J Med 1998; 338: 1641-1649.
8. Crofton J, Chaulet P, Maher D: Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997.
9. WHO Geneva/IUATLD Paris. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998; 2: 72-89.
10. Lemeshow S, Hosmer D W. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115: 92-106.
11. Canetti G, Le Lirzin M, Gay P, Thibier R, Kreis B, Grosset J. La resistance primaire dans la tuberculose pulmonaire de l'adulte en France. Rev Tuberc Pneumol 1972; 36: 337-357.
12. Howard W L, Maresh E, Muller E E, Yanitelli S A, Woodruff G F. The role of pulmonary cavitation in the development of bacterial resistance to streptomycin. Am Rev Tuberc 1949; 59: 391.
13. Cohn D L, Bustreo F, Raviglione M C. Drug-resistant tuberculosis: a review of the worldwide situation and the WHO/ IUATLD global surveillance project. Clin Infect Dis 1997; 24 (Suppl 1): S121-S130.
14. Middlebrook G, Cohn M L. Some observations on the pathogenicity of isoniazid resistant variants of tubercle bacilli. Science 1953; 118: 297-299.
15. Helbling P, Zellweger J P. TB drug resistance surveillance in Switzerland. Int J Tuberc Lung Dis 1997; 1 (Suppl 1): S27.
16. Lambregts-van Weezenbeek C S B, Jansen H M, Veen J, Nagelkerke N J D, Sebek M M G G, van Soolingen D. Origin and management of primary and acquired drug-resistant tuberculosis in The Netherlands: the truth behind the rates. Int J Tuberc Lung Dis 1998; 2: 296-302.
17. Ormerod L P, Harrison J M, Wright P A. Drug resistance trends in Mycobacterium tuberculosis: Blackburn 1985-1989. Tubercle 1990; 71: 283-285.
18. Schaberg T, Gloger G, Reichert B, Mauch H, Lode H. Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J 1995; 8: 278-284.
19. Grosset J, Trystram D, de Benoist A-C, et al. La tuberculose à bacilles multirésistants en France en 1995. Bull Epidémiol Hebdo 1998; 13: 53-54.
20. Lambregts-van Weezenbeek C S B, Jansen H M, Nagelkerke N J D, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. Int J Tuberc Lung Dis 1998; 2: 288-295.
21. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multidrug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.
22. Nolan C M, Williams D E, Cave M D, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995; 152: 1067-1071.
23. Moore M, Onorato I M, McCray E, Castro K G. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-837.
24. Ridzon R, Whitney C G, McKenna M T, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-1884.
25. Bishai W R, Graham N M H, Harrington S, et al. Rifampicin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996; 334: 1573-1576.
26. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153: 837-840.
27. Munsiff S, Joseph S, Ebrahimzadeh A, Frieden T R. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25: 1465-1467.
28. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847.
29. Centers for Disease Control and Prevention. Tuberculosis among foreign-born persons entering the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR 1990; 39(RR-18): 1-21.